Drug intelligence / Profile preview

Streptococcus pneumoniae type 23F capsular polysaccharide antigen

Development stage
Approved
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

Streptococcus pneumoniae type 23F capsular polysaccharide antigen is a highly purified bacterial capsular polysaccharide derived from the invasive serotype 23F of Streptococcus pneumoniae. It is used as an active immunization agent, administered intramuscularly or subcutaneously, to prevent diseases caused by S. pneumoniae, such as pneumococcal pneumonia and bacteremia. The mechanism of action involves inducing the production of type-specific antibodies that enhance opsonization and phagocytosis of the bacteria by immune cells. This antigen is included in multivalent vaccines like Pneumovax 23 (PPSV23), which contains purified capsular polysaccharides from multiple S. pneumoniae serotypes, including 23F[3][6][7]. These vaccines are primarily indicated for high-risk adults and children to reduce morbidity and mortality associated with invasive pneumococcal disease[4][6].

Brand names
Pneumovax 23Pneumovax23Pneumovax-23Prevnar 13Prevnar13Prevnar-13Vaxneuvance
Other names
PPSV23PPSV-23PPSV 23PPV-23PPV23PPV 23pneumococcal vaccine polyvalent
02

Targets

Streptococcus pneumoniae serotype 23F capsular polysaccharide

Beyond the preview

Go deeper on Streptococcus pneumoniae type 23F capsular polysaccharide antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae type 23F capsular polysaccharide antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call